Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 7/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13720957 | 0.91 | SMN1; SMN2 (0.47) | LMNAPOLBKMT2AKDM4EUSP2 | |
| SCHEMBL13721811 | 0.89 | KDM4E (0.46) | LMNAAKR1B1KMT2AKDM4E | |
| SCHEMBL16155973 | 0.82 | LMNA (0.57) | LMNAPOLBAKR1B1KMT2ACNR2 | |
| SCHEMBL1786577 | 0.81 | LMNA (0.52) | LMNAPOLBAKR1B1CNR2CXCR3 | |
| SCHEMBL30795856 | 0.81 | LMNA (0.52) | LMNAPOLBAKR1B1CNR2CXCR3 | |
| SCHEMBL13721293 | 0.81 | KDM4E (0.46) | LMNAAKR1B1KMT2AKDM4E | |
| SCHEMBL13720913 | 0.79 | ALDH1A1 (0.46) | LMNAKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL13720752 | 0.78 | CHRNA7 (0.37) | LMNAPOLBAKR1B1KMT2ACNR2 | |
| SCHEMBL13720840 | 0.76 | KDM4E (0.46) | LMNAAKR1B1KMT2AKDM4E | |
| SCHEMBL13720849 | 0.76 | KDM4E (0.44) | LMNAPOLBAKR1B1KMT2ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289500-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-11-15 | — | — | US | claimed |
| US-8859549-B2 | Potassium channel modulators | ABBVIE, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| WO-2012158399-A1 | CONDENSED 2 - CARBAMOYLPYRIDAZINONES AS POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20120289500-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289500-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNJ2 | LMNA 1022/4885POLB 4320/4885AKR1B1 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.